Amgen (NASDAQ:AMGN) Stock Price Target Raised at Cantor Fitzgerald

Amgen (NASDAQ:AMGN) had its target price lifted by Cantor Fitzgerald from $440.00 to $465.00 in a report issued on Wednesday morning, Marketbeat.com reports. They currently have a neutral rating on the medical research company’s stock.

Several other research analysts have also recently commented on AMGN. BMO Capital Markets reduced their price target on Amgen from $450.00 to $415.00 and set a “market perform” rating for the company in a research report on Monday, October 12th. Mizuho boosted their price target on Amgen from $303.00 to $352.00 and gave the stock a “neutral” rating in a research report on Tuesday, August 18th. Wall Street Zen upgraded Amgen from a “hold” rating to a “buy” rating in a research note on Sunday, October 18th. Barclays increased their price objective on Amgen from $380.00 to $400.00 and gave the company an “equal weight” rating in a report on Wednesday, October 21st. Finally, Scotiabank raised their target price on shares of Amgen from $450.00 to $500.00 and gave the company an “outperform” rating in a research note on Monday, September 28th. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, seventeen have assigned a Hold rating and three have issued a Sell rating to the company’s stock. According to MarketBeat, Amgen currently has an average rating of “Hold” and a consensus target price of $413.38.

Amgen Trading Up 3.7%

Amgen stock opened at $478.48 on Wednesday. The company has a market cap of $258.68 billion, a price-to-earnings ratio of 27.75, a P/E/G ratio of 3.38 and a beta of 0.43. The firm has a 50-day moving average of $421.56 and a 200-day moving average of $376.90. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.13. Amgen has a one year low of $302.13 and a one year high of $482.48.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, November 3rd. The medical research company reported $6.45 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.79 by $0.66. The business had revenue of $10.37 billion for the quarter, compared to the consensus estimate of $10.07 billion. Amgen had a return on equity of 128.15% and a net margin of 24.14%. Amgen’s quarterly revenue was up 8.5% on a year-over-year basis. During the same quarter in the previous year, the business earned $5.64 earnings per share. On average, equities analysts expect that Amgen will post 22.96 earnings per share for the current fiscal year.

Amgen Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, December 11th. Investors of record on Friday, November 20th will be paid a $2.52 dividend. This represents a $10.08 annualized dividend and a yield of 2.1%. The ex-dividend date is Friday, November 20th. Amgen’s dividend payout ratio (DPR) is 62.65%.

Insider Buying and Selling

In other Amgen news, SVP Rachna Khosla sold 2,000 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total transaction of $825,140.00. Following the transaction, the senior vice president owned 6,404 shares of the company’s stock, valued at $2,642,098.28. The trade was a 23.80% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.85% of the company’s stock.

Institutional Trading of Amgen

Several institutional investors and hedge funds have recently bought and sold shares of AMGN. 626 Financial LLC bought a new position in shares of Amgen in the third quarter valued at about $222,000. Csenge Advisory Group lifted its stake in shares of Amgen by 1.2% during the 3rd quarter. Csenge Advisory Group now owns 10,491 shares of the medical research company’s stock worth $4,422,000 after buying an additional 129 shares during the last quarter. D.B. Root & Company LLC lifted its stake in shares of Amgen by 9.3% during the 3rd quarter. D.B. Root & Company LLC now owns 738 shares of the medical research company’s stock worth $311,000 after buying an additional 63 shares during the last quarter. D Orazio & Associates Inc. lifted its stake in shares of Amgen by 4.4% during the 3rd quarter. D Orazio & Associates Inc. now owns 3,231 shares of the medical research company’s stock worth $1,362,000 after buying an additional 135 shares during the last quarter. Finally, New York Life Investment Management LLC boosted its holdings in shares of Amgen by 1.6% during the 3rd quarter. New York Life Investment Management LLC now owns 88,055 shares of the medical research company’s stock worth $37,116,000 after buying an additional 1,378 shares during the period. Institutional investors own 76.50% of the company’s stock.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen reported adjusted earnings of $6.45 per share and revenue of $10.37 billion, topping analyst estimates; revenue increased 8.5% year over year. The company also raised its 2026 outlook to $38.9 billion–$39.7 billion in revenue and $18.34–$19.28 in GAAP EPS. Amgen third-quarter financial results
• Positive Sentiment: Growth in medicines including Repatha and IMDELLTRA helped offset pressure elsewhere. Amgen also highlighted pipeline progress, including IMDELLTRA and potential longer-term growth from its obesity candidate MariTide. Amgen raises 2026 outlook
• Positive Sentiment: Several firms raised their targets, including UBS and Scotiabank to $530 and Goldman Sachs to $536, with buy or outperform ratings. These revisions suggest some analysts see further upside after the results. Analyst views and revised targets
• Neutral Sentiment: Analyst opinion remains divided: some target increases still leave estimates below the prevailing share price, and MariTide data is a future catalyst rather than a near-term result. RBC Capital adjusts Amgen target
• Negative Sentiment: Investors remain concerned about steep declines in Prolia and Xgeva as biosimilar competition weighs on sales. That erosion may limit how much growth from newer products translates into future results. Sales and biosimilar concerns

Amgen Company Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company’s products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.